GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Alvotech (NAS:ALVOW) » Definitions » Common Stock

Alvotech (Alvotech) Common Stock : $2.60 Mil (As of Mar. 2024)


View and export this data going back to 2022. Start your Free Trial

What is Alvotech Common Stock?

Alvotech's quarterly common stock increased from Sep. 2023 ($2.27 Mil) to Dec. 2023 ($2.28 Mil) and increased from Dec. 2023 ($2.28 Mil) to Mar. 2024 ($2.60 Mil).

Alvotech's annual common stock increased from Dec. 2021 ($0.14 Mil) to Dec. 2022 ($2.13 Mil) and increased from Dec. 2022 ($2.13 Mil) to Dec. 2023 ($2.28 Mil).


Alvotech Common Stock Historical Data

The historical data trend for Alvotech's Common Stock can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Alvotech Common Stock Chart

Alvotech Annual Data
Trend Dec19 Dec20 Dec21 Dec22 Dec23
Common Stock
- 0.07 0.14 2.13 2.28

Alvotech Quarterly Data
Dec19 Dec20 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Common Stock Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 2.28 2.27 2.27 2.28 2.60

Alvotech Common Stock Calculation

Common stock is listed on the Balance Sheet at the par value of the total shares outstanding of a company.

The par value of common stocks is meaningless. It is usually set at an absurdly low number.


Alvotech (Alvotech) Business Description

Traded in Other Exchanges
Address
9, rue de Bitbourg, Luxembourg, LUX, L-1273
Alvotech is an integrated biopharmaceutical company committed to developing and manufacturing high-quality biosimilar medicines for patients globally. its purpose is to improve the health and quality of life of patients around the world by improving access to proven treatments for various diseases.